International Biotechnology Trust’s Global Blood Therapeutics, Inc. GBT Stock Holding History

International Biotechnology Trust’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-151,800	Closed	-$1.64M	–	83
2022 Q1	$1.64M	Buy	151,800 +57,000	+60%	+$1.7M	0.37%	45
2021 Q4	$2.77M	Buy	94,800 +73,000	+335%	+$2.26M	0.62%	38
2021 Q3	$555K	Hold	21,800	–	–	0.13%	58
2021 Q2	$763K	Hold	21,800	–	–	0.2%	55
2021 Q1	$888K	Hold	21,800	–	–	0.23%	49
2020 Q4	$944K	Hold	21,800	–	–	0.26%	45
2020 Q3	$1.2M	Buy	21,800 +12,000	+122%	+$763K	0.39%	39
2020 Q2	$652K	Hold	9,800	–	–	0.22%	49
2020 Q1	$498K	Sell	9,800 -13,300	-58%	-$891K	0.23%	52
2019 Q4	$1.84M	Buy	23,100 +4,600	+25%	+$273K	0.66%	34
2019 Q3	$897K	Sell	18,500 -9,500	-34%	-$495K	0.41%	43
2019 Q2	$1.47M	Hold	28,000	–	–	0.55%	44
2019 Q1	$1.48M	Buy	+28,000	New	+$1.38M	0.55%	48
2017 Q3	–	Sell	-20,500	Closed	-$561K	–	67
2017 Q2	$561K	Sell	20,500 -37,500	-65%	-$1.12M	0.21%	59
2017 Q1	$2.13M	Buy	+58,000	New	+$1.46M	0.82%	31

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

International Biotechnology Trust's GBT Position: Q2 2022 in Review

International Biotechnology Trust sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2022, closing a stake of 151,800 shares — an estimated $1.64M sold.

International Biotechnology Trust first reported a position in GBT in Q1 2017 and held it in 15 quarters. The position peaked at $2.77M in Q4 2021. 195 funds tracked by Wall St. Rank hold GBT as of Q2 2022.

International Biotechnology Trust reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
International Biotechnology Trust sold 151,800 Global Blood Therapeutics, Inc. shares in Q2 2022, an estimated $1.64M.
International Biotechnology Trust first reported a position in Global Blood Therapeutics, Inc. in Q1 2017 and held it in 15 quarters.
International Biotechnology Trust's Global Blood Therapeutics, Inc. position peaked at $2.77M in Q4 2021.
195 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2022.

Based on International Biotechnology Trust's 13F filing for Q2 2022, filed 16 Aug 2022.